iXCells Biotechnologies USA, Inc., a cell technology company that offers cell-based products and drug discovery service solutions, has announced the appointment of Helge Bastian, PhD, as its new CEO.
Dr. Bastian is a seasoned leader in the life sciences and healthcare sector, with experience in building and growing businesses for small and large companies. He has held senior positions at Thermo Fisher Scientific, Sigma-Aldrich, SGS, QIAGEN, Indivumed, and M2GEN. He also serves as a Board Member of Molecular Assemblies and a Strategic Advisor of PreComb Therapeutics.
Dr. Bastian will lead iXCells Biotechnologies USA in its next phase of growth, leveraging its expertise in iPSC reprogramming, genome editing, stem cell differentiation, and cell-based assays. He will also focus on supporting the rare disease community in developing cell-based solutions and therapies.
He expressed his admiration for iXCells’ scientific and technology excellence, and his gratitude for joining the company at this important stage.
Lynn Zhang, the co-founder and former CEO of iXCells Biotechnologies USA, welcomed Dr. Bastian to the executive team and praised his entrepreneurial and intrapreneurial leadership skills. She also highlighted iXCells’ remarkable transformation and expansion over the past few years, and its commitment to delivering the best service to its customers worldwide.